[go: up one dir, main page]

Richards et al., 1992 - Google Patents

Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure

Richards et al., 1992

Document ID
2001354261724109987
Author
Richards A
Crozier I
Espiner E
Ikram H
Yandle T
Kosoglou T
Rallings M
Frampton C
Publication year
Publication venue
Journal of cardiovascular pharmacology

External Links

Snippet

The acute renal, endocrine, and hemodynamic effects of the orally active endopeptidase inhibitor SCH 34826 (400 mg every 6 hours for five doses) were investigated in a group of 6 male patients [with established mild to moderate essential hypertension and left ventricular …
Continue reading at journals.lww.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof

Similar Documents

Publication Publication Date Title
Manabe et al. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension
Agarwal Add-on angiotensin receptor blockade with maximized ACE inhibition
McClean et al. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure
Krishna et al. Protein-induced glomerular hyperfiltration: role of hormonal factors
PUDDEY et al. Alcohol, hypertension and the cardiovascular system: a critical appraisal
Schoppet et al. Alcohol and the heart
Fisher et al. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans.
Boschmann et al. Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin–angiotensin system activity in obese hypertensive patients
Richards et al. Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension.
Damjanovi et al. Fat intake and cardiovascular response
Dai et al. Differences in the Responses of the Pituitary β‐Endorphin and Cardiovascular System to Ethanol and Stress as a Function of Family History
Richards et al. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure
Li et al. Development of angiotensin II-induced hypertension: role of CGRP and its receptor
Kobrin et al. Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension
Plovsing et al. Effects of truncated angiotensins in humans after double blockade of the renin system
Singer et al. Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension.
Hadžiomerović et al. Normalization of hyperinsulinemia by chronic opioid receptor blockade in hyperandrogenemic women
Nakagawa et al. Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities
Wamberg et al. Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs
Shepherd et al. The influence of captopril, the nitrates and propranolol on apparent liver blood flow.
Bani et al. A double‐blind, placebo‐controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers
Jardine et al. The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and causes a natriuresis in normal humans
Ahlborg et al. Splanchnic and renal vasoconstriction during neuropeptide Y infusion in healthy humans
Asthana et al. Neuroendocrine responses to intravenous infusion of arecoline in patients with Alzheimer's disease
Portaluppi et al. Loss of the nocturnal increase in plasma concentration of atrial natriuretic peptide in hypertensive chronic renal failure